FY2024 EPS Estimates for Ascendis Pharma A/S Lifted by Cantor Fitzgerald (NASDAQ:ASND)

Ascendis Pharma A/S (NASDAQ:ASND) – Equities research analysts at Cantor Fitzgerald raised their FY2024 earnings per share estimates for Ascendis Pharma A/S in a note issued to investors on Monday, September 16th. Cantor Fitzgerald analyst L. Watsek now expects that the biotechnology company will post earnings per share of ($6.54) for the year, up from their previous estimate of ($6.59). Cantor Fitzgerald has a “Overweight” rating and a $170.00 price target on the stock. The consensus estimate for Ascendis Pharma A/S’s current full-year earnings is ($6.83) per share.

Several other brokerages have also issued reports on ASND. The Goldman Sachs Group lifted their price target on Ascendis Pharma A/S from $180.00 to $200.00 and gave the stock a “buy” rating in a research note on Tuesday. StockNews.com upgraded Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a report on Thursday, September 5th. JPMorgan Chase & Co. reduced their price target on Ascendis Pharma A/S from $174.00 to $165.00 and set an “overweight” rating on the stock in a report on Wednesday, September 4th. Citigroup upped their target price on Ascendis Pharma A/S from $178.00 to $207.00 and gave the stock a “buy” rating in a report on Tuesday. Finally, Stifel Nicolaus started coverage on Ascendis Pharma A/S in a research report on Friday, May 31st. They issued a “buy” rating and a $200.00 price target on the stock. Two analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $193.77.

Ascendis Pharma A/S Stock Up 1.6 %

Shares of ASND stock opened at $148.88 on Wednesday. The business has a 50-day moving average price of $132.71 and a two-hundred day moving average price of $136.43. Ascendis Pharma A/S has a 12-month low of $85.29 and a 12-month high of $161.00. The firm has a market cap of $8.67 billion, a P/E ratio of -15.22 and a beta of 0.63.

Hedge Funds Weigh In On Ascendis Pharma A/S

A number of large investors have recently made changes to their positions in the business. Quarry LP grew its holdings in shares of Ascendis Pharma A/S by 257.1% during the second quarter. Quarry LP now owns 2,500 shares of the biotechnology company’s stock valued at $341,000 after buying an additional 1,800 shares during the last quarter. Algert Global LLC boosted its stake in shares of Ascendis Pharma A/S by 54.6% during the 2nd quarter. Algert Global LLC now owns 2,180 shares of the biotechnology company’s stock worth $297,000 after acquiring an additional 770 shares in the last quarter. Lighthouse Investment Partners LLC purchased a new stake in shares of Ascendis Pharma A/S during the 2nd quarter worth about $2,762,000. Fred Alger Management LLC raised its position in shares of Ascendis Pharma A/S by 65.0% during the 2nd quarter. Fred Alger Management LLC now owns 307,073 shares of the biotechnology company’s stock worth $41,879,000 after purchasing an additional 120,952 shares during the last quarter. Finally, First Light Asset Management LLC acquired a new position in shares of Ascendis Pharma A/S during the 2nd quarter worth about $4,931,000.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.